Literature DB >> 11774962

Acute interstitial nephritis due to omeprazole.

R P Myers1, K McLaughlin, D J Hollomby.   

Abstract

Omeprazole is a proton pump inhibitor that is used commonly in the treatment of acid-peptic disorders. Although omeprazole is generally well tolerated, serious adverse effects such as renal failure have been reported. Thus far, 17 cases of acute interstitial nephritis (AIN) secondary to omeprazole have been described. Another case of AIN is described in a 36-yr-old woman presenting with nausea, vomiting, weight loss, and a rising serum creatinine concentration. Omeprazole therapy had ceased 2 wk before admission. AIN was diagnosed by renal biopsy and corticosteroid therapy was initiated. After 4 wk of therapy the serum creatinine concentration had normalized. Among the reported cases in the literature, AIN was diagnosed after an average of 2.7 months of therapy with 20-40 mg of omeprazole daily. Recurrence was universal on rechallenge. Common symptoms included fatigue, fever, anorexia, and nausea. The classic triad of fever, rash, and eosinophilia was uncommon. Typical laboratory features included hematuria, proteinuria, pyuria, eosinophilia, and anemia. Management consisted of withdrawal of omeprazole and corticosteroid therapy in some patients. All but one patient recovered normal renal function. Corticosteroid therapy was well tolerated and may have been beneficial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774962     DOI: 10.1111/j.1572-0241.2001.05345.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

Review 1.  Risk factors for gastrointestinal complications in aspirin users: review of clinical and experimental data.

Authors:  Felix W Leung
Journal:  Dig Dis Sci       Date:  2008-02-28       Impact factor: 3.199

2.  Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness.

Authors:  Joon Lee; Roger G Mark; Leo Anthony Celi; John Danziger
Journal:  J Clin Pharmacol       Date:  2016-09-12       Impact factor: 3.126

Review 3.  PPIs and kidney disease: from AIN to CKD.

Authors:  Dennis G Moledina; Mark A Perazella
Journal:  J Nephrol       Date:  2016-04-12       Impact factor: 3.902

4.  A Retrospective Study to Assess the Effect of Proton Pump Inhibitors on Renal Profile in a South Indian Hospital.

Authors:  A Avinash; Navin Patil; Sushil Kiran Kunder; O Balaji; Amod Tilak; Ravi K Sori; Raghavendra Rao
Journal:  J Clin Diagn Res       Date:  2017-04-01

Review 5.  Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity.

Authors:  Xiao Wei; Jun Yu; Zhengkun Xu; Chun Wang; Yonggui Wu
Journal:  Drug Saf       Date:  2022-06-01       Impact factor: 5.228

6.  Cellulose acetate membrane electrophoresis in the analysis of urinary proteins in patients with tubulointerstitial nephritis.

Authors:  Ryo Kubota; Ryoko Machii; Nobuo Hiratsuka; Osamu Hotta; Yoshihisa Itoh; Shizuko Kobayashi; Kiyoko Shiba
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

7.  Acute interstitial nephritis due to proton pump inhibitors.

Authors:  K Sampathkumar; R Ramalingam; A Prabakar; A Abraham
Journal:  Indian J Nephrol       Date:  2013-07

8.  Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist?

Authors:  Stephanie Toth-Manikowski; Morgan E Grams
Journal:  Kidney Int Rep       Date:  2017-01-23

9.  Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids.

Authors:  Maria Prendecki; Anisha Tanna; Alan D Salama; Frederick W K Tam; Tom Cairns; David Taube; H Terence Cook; Damien Ashby; Neil D Duncan; Charles D Pusey
Journal:  Clin Kidney J       Date:  2016-12-24

10.  Omeprazole Alleviates Aristolochia manshuriensis Kom-Induced Acute Nephrotoxicity.

Authors:  Lianmei Wang; Hongbing Zhang; Chunying Li; Yan Yi; Jing Liu; Yong Zhao; Jingzhuo Tian; Yushi Zhang; Xiaolu Wei; Yue Gao; Aihua Liang
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.